Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation
oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital